Anthony Mato, MD
Memorial Sloan Kettering Cancer Center · Abramson Cancer Center at Penn Medicine · University of Pennsylvania Center for CLL
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Anthony Mato, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:56 UTC. Open this list on ClinicalTrials.gov
- N/ANCT04694560 · A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaMemorial Sloan Kettering Cancer Center · withdrawn · CLL, SLL, CLL/SLL · principal investigator
- N/ANCT02993536 · Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximabAbramson Cancer Center at Penn Medicine · withdrawn · Chronic Lymphocytic Leukemia · principal investigator
- Ph2NCT02742090 · Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior TherapyTG Therapeutics, Inc. · terminated · Chronic Lymphocytic Leukemia · study chair
- Ph2NCT01241786 · Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLLHackensack Meridian Health · terminated · Chronic Lymphocytic Leukemia(CLL), Small Lymphocytic Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:57 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.